BioCryst Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-07$7.92 RISE2026-02-05$6.24 PEAK2026-04-09$9.89 92d | -21.2% 29d | Missed | Missed | — | — | +58.5% 63d | Missed |
DROP2025-06-09$11.11 RISE2025-10-14$6.42 PEAK2026-01-07$7.92 212d | -42.2% 127d | Missed | Missed | — | — | +23.4% 85d | Missed |
DROP2025-02-20$9.39 RISE2025-04-10$6.41 PEAK2025-06-03$11.19 103d | -31.7% 49d | Missed | Missed | — | — | +74.6% 54d | Missed |
DROP2024-11-01$8.43 RISE2025-01-16$7.06 PEAK2025-02-19$9.39 110d | -16.3% 76d | Missed | Missed | — | — | +33.0% 34d | Missed |
DROP2024-08-30$8.69 RISE2024-11-15$7.03 PEAK2025-02-14$9.05 168d | -19.1% 77d | Missed | Missed | — | — | +28.7% 91d | Missed |
DROP2024-01-08$7.65 RISE2024-04-30$4.13 PEAK2024-07-26$7.85 200d | -46.0% 113d | Missed | Missed | — | — | +90.1% 87d | Missed |
DROP2024-01-08$7.65 RISE2024-02-02$5.08 PEAK2024-02-12$5.95 35d | -33.6% 25d | Missed | Missed | — | — | +17.1% 10d | Missed |
DROP2023-07-26$7.92 RISE2023-11-10$4.98 PEAK2024-01-08$7.65 166d | -37.1% 107d | Missed | Missed | — | — | +53.6% 59d | Missed |
DROP2023-01-04$11.84 RISE2023-05-02$7.37 PEAK2023-06-07$8.81 154d | -37.8% 118d | Missed | Missed | — | — | +19.5% 36d | Missed |
DROP2022-08-24$14.81 RISE2022-09-26$12.11 PEAK2022-10-06$14.20 43d | -18.2% 33d | Missed | Missed | — | — | +17.3% 10d | Missed |
DROP2022-02-16$19.76 RISE2022-05-12$7.89 PEAK2022-08-09$14.45 174d | -60.1% 85d | Missed | Missed | — | — | +83.1% 89d | Missed |
DROP2021-08-09$17.65 RISE2021-12-06$11.18 PEAK2022-02-16$19.76 191d | -36.7% 119d | Missed | Missed | — | — | +76.7% 72d | Missed |
DROP2021-08-09$17.65 RISE2021-10-04$13.31 PEAK2021-10-25$15.46 77d | -24.6% 56d | Missed | Missed | — | — | +16.2% 21d | Missed |
DROP2021-03-10$13.61 RISE2021-04-12$9.50 PEAK2021-06-07$17.24 89d | -30.2% 33d | Missed | Missed | — | — | +81.5% 56d | Missed |
DROP2020-07-09$5.53 RISE2020-10-02$3.37 PEAK2020-12-18$8.61 162d | -39.1% 85d | Missed | Missed | — | — | +155.5% 77d | Missed |
1–15 / 18 1 / 2 | |||||||
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only target
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026. Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating
Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of
BioCryst Pharmaceuticals, Inc. (BCRX) Bank of America Global Healthcare Conference 2026 May 12, 2026 4:40 PM EDTCompany ParticipantsBabar Ghias - CFO &...
BioCryst Pharmaceuticals reported first-quarter 2026 results with revenue of US$156.41 million, up from US$145.53 million a year earlier, but moved from a small profit to a net loss of US$721.81 million, while maintaining full‑year revenue guidance of US$635 million to US$660 million. Alongside these results, the company entered a licensing agreement giving an Irish affiliate of Neopharmed Gentili exclusive European rights to navenibart for hereditary angioedema, bringing in US$70 million...
BioCryst Pharmaceuticals reported first-quarter 2026 results with revenue of US$156.41 million, up from US$145.53 million a year earlier, but moved from a small profit to a net loss of US$721.81 million, while maintaining full‑year revenue guidance of US$635 million to US$660 million. Alongside these results, the company entered a licensing agreement giving an Irish affiliate of Neopharmed Gentili exclusive European rights to navenibart for hereditary angioedema, bringing in US$70 million...
BioCryst Pharmaceuticals (BCRX) is back in focus after first quarter results combined higher revenue with a very large reported loss, alongside a fresh licensing deal for navenibart in Europe and reaffirmed full year revenue guidance. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $8.58, BioCryst’s 90 day share price return of 30.99% and year to date gain of 14.40% contrast with a decline of 17.02% in the 1 year total shareholder return. This suggests that momentum...
BioCryst Pharmaceuticals (BCRX) is back in focus after first quarter results combined higher revenue with a very large reported loss, alongside a fresh licensing deal for navenibart in Europe and reaffirmed full year revenue guidance. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $8.58, BioCryst’s 90 day share price return of 30.99% and year to date gain of 14.40% contrast with a decline of 17.02% in the 1 year total shareholder return. This suggests that momentum...
BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.
Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the price target from $25 to $28.
Discover why small-cap indexes lag large caps and how active screening with an enhanced Magic Formula can uncover small-cap value and manage riskâread now.
Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $22 to $21.
2026 is off to a very good start for BioCryst, marked by strong execution on our commercial and development programs, the smooth integration of Astria Therapeutics and disciplined management of our finances. ORLADEYO net revenue of $148.3 million for the quarter was right in line with our expectations, and monthly new patient prescriptions have tracked slightly ahead of 2025 averages. The pediatric launch -- pediatric indication launch is just beginning, but early signals confirm the need for oral prophylaxis for kids with HAE.
2026 is off to a very good start for BioCryst, marked by strong execution on our commercial and development programs, the smooth integration of Astria Therapeutics and disciplined management of our finances. ORLADEYO net revenue of $148.3 million for the quarter was right in line with our expectations, and monthly new patient prescriptions have tracked slightly ahead of 2025 averages. The pediatric launch -- pediatric indication launch is just beginning, but early signals confirm the need for oral prophylaxis for kids with HAE.
Moby summary of BioCryst Pharmaceuticals, Inc.'s Q1 2026 earnings call
Moby summary of BioCryst Pharmaceuticals, Inc.'s Q1 2026 earnings call
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCRX | -3.05% | +3.24% | +14.23% | -17.12% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.02% | +8.96% | +17.67% | -29.80% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 12.21M | $116.22M | 0.00% | Added+10.3% | 2026-03-31 |
| TwoSigma | quant | 6.39M | $60.86M | 0.05% | Added+41.6% | 2026-03-31 |
| RenTech | quant | 777.0K | $7.40M | 0.01% | Trimmed-63.5% | 2026-03-31 |
| Bridgewater | macro | 638.1K | $6.07M | 0.03% | Added+170.9% | 2026-03-31 |
| FidelityFMR | fundamental | 633.1K | $6.03M | 0.00% | Added+13.0% | 2026-03-31 |
| DEShaw | quant | 302.1K | $2.88M | 0.00% | Trimmed-75.8% | 2026-03-31 |
| Wellington | fundamental | 98.9K | $941.37K | 0.00% | Added+14.3% | 2026-03-31 |
| TRowePrice | fundamental | 231.0K | $2.20K | 0.00% | Added+30.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | 0.25 | — | — |
| 2026-05-06 | 0.11 | 0.14 | +27.68% |
| 2026-02-26 | 0.07 | 0.21 | +197.57% |
| 2025-11-03 | 0.07 | 0.16 | +125.29% |
| 2025-08-04 | 0.03 | 0.04 | +47.12% |
| 2025-05-05 | -0.05 | — | +100.00% |
| 2025-02-24 | -0.05 | -0.13 | -137.49% |
| 2024-11-04 | -0.08 | -0.07 | +17.42% |
| 2024-08-05 | -0.16 | -0.06 | +63.28% |
| 2024-05-06 | -0.23 | -0.17 | +26.03% |
| 2024-02-26 | -0.22 | -0.28 | -25.64% |
| 2023-11-02 | -0.19 | -0.19 | — |
| 2023-08-03 | -0.21 | -0.24 | -12.28% |
| 2023-05-03 | -0.29 | -0.28 | +1.95% |
| 2023-02-21 | -0.20 | -0.38 | -90.59% |
| 2022-11-01 | -0.26 | -0.23 | +13.14% |